As such, NGS can become a practical solution for a larger-scale adoption of anti-HER2 targeted therapy in the tumor-agnostic setting or after multiple lines of therapy have been exhausted [14,22,72,73]. This evidence concerns the gene ERBB2 and neoplasm.